Unknown

Dataset Information

Neutralizing activity to SARS-CoV-2 of convalescent and control plasma used in a randomized controlled trial.


ABSTRACT:

Background

There are limited data on the neutralizing activity of convalescent plasma (CP) administered in randomized controlled trials (RCT) of COVID-19 infection.

Study design and methods

As part of an RCT, CP was collected per FDA guidelines from individuals recovered from COVID-19 infection. CP donors had to have ≥145 optical density (OD) units (ideal target ≥300) using a semiquantitative, immunochromatographic test for IgG antibody to the nucleocapsid protein (NP) of SARS-CoV-2 (typical range 0-500 OD units). A random subset of samples [14 control plasma, 12 CP "medium-anti-NP" (145-299 OD units), and 13 CP "high" anti-NP (≥300 OD units)] were tested for neutralizing antibodies using an established viral luciferase antibody inhibition assay to detect the infection of SA

SUBMITTER: Freedenberg AT 

PROVIDER: S-EPMC8014203 | biostudies-literature | 2021 May

REPOSITORIES: biostudies-literature